Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 8/20 | 0.85 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.85 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.43 |
| ▸ | PARG | Q86W56 | 3/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6244295 | 0.92 | MMP13 (1.00) | MMP13SLC22A8HDAC1HDAC11HDAC8 | |
| SCHEMBL6390652 | 0.90 | MMP13 (0.78) | MMP13SLC22A8HDAC1HDAC11HDAC8 | |
| SCHEMBL6397427 | 0.90 | MMP13 (0.91) | MMP13SLC22A8HDAC1PARG | |
| SCHEMBL6231376 | 0.89 | MMP13 (0.82) | MMP13SLC22A8HDAC1HDAC11HDAC8 | |
| SCHEMBL6396665 | 0.87 | MMP13 (0.66) | MMP13SLC22A8HDAC1HDAC11HDAC8 | |
| SCHEMBL6238935 | 0.86 | MMP13 (0.61) | MMP13SLC22A8HDAC1HDAC11HDAC8 | |
| SCHEMBL6390967 | 0.85 | MMP13 (0.87) | MMP13SLC22A8HDAC1HDAC11HDAC8 | |
| SCHEMBL6390295 | 0.85 | MMP13 (0.63) | MMP13SLC22A8PARG | |
| SCHEMBL6390853 | 0.85 | MMP13 (0.62) | MMP13SLC22A8PARGGRM4 | |
| SCHEMBL6392927 | 0.85 | MMP13 (0.83) | MMP13SLC22A8HDAC1HDAC11HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962922-B2 | Alkynylated quinazoline compounds | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050245548-A1 | Alkynylated fused ring pyrimidine compounds | GAUDILLIERE BERNARD | 2005-11-03 | — | — | US | disclosed |
| US-20030130278-A1 | Alkynylated fused ring pyrimidine compounds | GAUDILLIERE BERNARD (FR) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130278-A1 | Alkynylated fused ring pyrimidine compounds | MMP13, TIMP3, MMP3 | MMP13 1/4885SLC22A8 811/4885HDAC1 1073/4885 |
| US-20050245548-A1 | Alkynylated fused ring pyrimidine compounds | MMP13, TIMP3, MMP3 | MMP13 1/4885SLC22A8 827/4885HDAC1 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.